Drug Trial Radar · NCT06235151
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
443
Actual
Start
Apr 1, 2024
Primary completion
Oct 30, 2026
Study completion Oct 30, 2026
Sponsor
- Lead sponsor
- Curium US LLCIndustry
- Sponsor type
- Industry
- First posted
- Jan 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
Conditions
- Prostate Cancer
- Prostate Adenocarcinoma
Interventions
Copper Cu 64 PSMA I&TDrug
Radiopharmaceutical PET imaging tracer injected intravenously for staging of prostate cancer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- SensitivityTime frame: 4 Hours
- SpecificityTime frame: 4 Hours
Locations
43 sites in 1 country. Site status is shown where the registry gives one.
Urology Centers of Alabama
Homewood, Alabama
Arkansas Urology
Little Rock, Arkansas
Providence Medical Foundation
Fullerton, California
Tower Urology
Los Angeles, California
VA Greater Los Angeles Healthcare System
Los Angeles, California
Hoag Memorial Hospital Presbyterian
Newport Beach, California
University of California, Irvine
Orange, California
San Francisco VA Medical Center
San Francisco, California
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Providence Saint John's Health Center
Santa Monica, California
Stanford Hospital & Clinics
Stanford, California
Georgetown University Medical Center
Washington D.C., District of Columbia
University of Miami Hospital and Clinics - Sylvester Comprehensive Cancer Center
Miami, Florida
CIRA Health
Miami, Florida
Sarasota Memorial Health Care System
Sarasota, Florida
Florida Urology Partners
Tampa, Florida
Edward Hines Jr. VA Hospital
Hines, Illinois
Urology of Indiana, LLC
Carmel, Indiana
IU Health Neuroscience Center
Indianapolis, Indiana
University of Iowa
Iowa City, Iowa
The University of Kansas Hospital
Kansas City, Kansas
United Theranostics
Glen Burnie, Maryland
VA Boston Healthcare System
Boston, Massachusetts
M Health Fairview University of Minnesota Medical Center
Minneapolis, Minnesota
SSM Health Saint Louis University Hospital
St Louis, Missouri
John Cochran VA Medical Center
St Louis, Missouri
Great Plains Health, Diagnostic Imaging
North Platte, Nebraska
XCancer
Omaha, Nebraska
United Theranostics
Princeton, New Jersey
Adaptive Research Inc.
Hawthorne, New York
Columbia University Medical Center
New York, New York
James J. Peters VA Medical Center
The Bronx, New York
UNC Cancer Center
Chapel Hill, North Carolina
Cleveland Clinic
Cleveland, Ohio
Dayton Physicians Network / Greater Dayton Cancer Center
Kettering, Ohio
VA Portland Health Care System
Portland, Oregon
Hollings Cancer Center
Charleston, South Carolina
Carolina Urologic Research Center, LLC
Myrtle Beach, South Carolina
University of Tennessee Medical Center
Knoxville, Tennessee
Excel Diagnostics and Nuclear Oncology Center
Houston, Texas
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.